3 6 Ke·2026-02-12 13:53Core Viewpoint - The article discusses the transformative impact of AI in the medical field, particularly in enhancing decision-making processes for complex diseases like cancer, while addressing the financial uncertainties faced by patients [3][4]. Group 1: Medical AI Development - OpenEvidence, a medical AI startup, completed a Series D funding round, achieving a valuation of $12 billion, and is used by over 40% of practicing physicians in the U.S. [3] - Chinese tech giants are entering the medical AI space, with Ping An focusing on building an AI-MDT platform that integrates deep diagnosis and risk control, aiming for a more comprehensive approach than just a Q&A tool [4][5]. Group 2: Business Models in Medical AI - The medical AI landscape features two main business paths: the "dialogue path" led by internet giants, which focuses on general AI capabilities, and the "vertical tool path" represented by startups like OpenEvidence, which provide specialized information but do not address patient care directly [5][6]. - Ping An is pursuing a unique "diagnosis + payment" model, emphasizing value-based healthcare and risk management, which distinguishes it from other players in the market [6][7]. Group 3: AI-MDT Platform Features - Ping An's AI-MDT platform targets serious diseases, particularly cancer, and aims to streamline complex treatment decisions through a three-layer capability advantage: authoritative evidence-based medical foundation, deep diagnostic decision-making logic, and a commercial insurance payment and risk control system [7][8]. - The platform leverages a vast network of 50,000 collaborating physicians and real-world cancer case data to enhance AI decision-making accuracy and align it with expert opinions [8]. Group 4: Patient and Insurance Engagement - The AI-MDT service offers structured second opinions to patients, providing in-depth analysis and recommendations for treatment plans, which are verified by renowned experts [10][11]. - The integration of AI in the insurance sector aims to reduce costs while maintaining quality, creating a sustainable model that benefits both patients and insurers [11][12]. Group 5: Future Directions - Ping An plans to expand the AI-MDT service to cover more prevalent serious diseases and improve the accuracy of treatment recommendations to 90% by 2026, ensuring 100% traceability of evidence used [12].